scispace - formally typeset
P

Peter C. Burger

Researcher at Harvard University

Publications -  143
Citations -  37212

Peter C. Burger is an academic researcher from Harvard University. The author has contributed to research in topics: Glioma & Anaplastic astrocytoma. The author has an hindex of 64, co-authored 142 publications receiving 35714 citations. Previous affiliations of Peter C. Burger include University of North Carolina at Chapel Hill & Massachusetts Institute of Technology.

Papers
More filters
Journal ArticleDOI

Sonographic characteristics of small cerebral blood vessels - an in vivo and postmortem study

TL;DR: It is demonstrated that small branches of the major intracranial blood vessels can be imaged as linear echoes and closely spaced dots by high-resolution sonography, and recognized the vascular origin of these echoes to avoid the pitfall of misinterpreting them as originating from pathologic processes such as periventricular leukomalacia.
Journal ArticleDOI

The MEK1/2 Inhibitor AZD6244 (ARRY-142886) Downregulates Constitutive and Adhesion-Induced c- MAF Oncogene Expression and Its Downstream Targets in Human Multiple Myeloma.

TL;DR: A role for c-MAF in the pathological interactions between MM cells and BMSCs is confirmed and an important role of the MEK/ERK activation in the ~40% of c- MAF -overexpressing myeloma cells that lack c-MAF translocations is defined.
Book ChapterDOI

Chromosomes and chromosomal progression of malignant human gliomas: theoretical and practical implications

TL;DR: The observa-tion that near-diploid human gliomas double their chromosome complements as they establish in culture and as transplantable lines in nude mice suggests that the near-tetraploid tumors in Group II are at a later stage of karyotypic progression than the near -diploids tumors in Groups I and III.
Journal ArticleDOI

Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.

TL;DR: It is proposed that serum CS1 will be an unlikely antibody sink in patients treated with optimal doses of HuLuc63, and suggested that circulating CS1 may indicate need for therapy and further support clinical investigation of anti-CS1 therapy using Hu Luc63 in MM.